Senores Pharmaceuticals Limited has informed the exchange about subsidiary companies capacity expansion

Date: October 29, 2026 To, To, Sr. General Manager Sr. General Manager BSE Limited National Stock Exchange of India Limited Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Sub.: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Ma’am, We are pleased to inform you that the Board of Directors of the Company at their meeting held today, i.e., Thursday, October 29, 2026, has noted that the Company’s various subsidiary companies have planned capacity expansion in their existing manufacturing facilities. The details of the indicative capacity expansions are as below: Name of the Existing Capacity (per Enhanced Capacity Estimated Cost (INR in Subsidiary annum) (per annum) Cr) Havix Group INC, USA 1.2 Bn units 2.0 Bn units 18.00 Apnar Pharma Private 0.5 Bn units 1.2 Bn units 20.00 Limited, India In addition to the above the Board has also noted that the subsidiary company Ratnatris Pharmaceuticals Private Limited is in process of adding a new Prefilled Syringe (PFS) line with a capacity of 2.7 Mn units (per annum) at an estimated cost of INR 5.00 Crores. All the proposed expansions are likely to be completed by end of March 2027. As a part of Good Corporate Governance and with a view of maintaining transparency and keeping investors and other stakeholders informed, the Company wishes to place the above information on record. The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Annexure- A. Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 You are requested to take the same on record. TFohra nSkeinnogr yeosu P. harmaceuticals Limited Shilpa Sharma Company Secretary & Compliance Officer Membership Number: A34516 Annexure-A Sr. Particulars Havix Group INC, USA Apnar Pharma Private No (subsidiary) Limited 1. Existing capacity 1.2 Bn units 0.5 Bn units 2. Existing Capacity utilisation Approximately 50-70% 3. Proposed capacity addition 0.8 Bn units 0.7 Bn units 4. Period within which the The proposed capacity addition to be completed by end of proposed capacity is to be March 2027 added 5. Investment required INR 18.00 crores INR 20.00 crores 6. Mode of financing Internal accruals and IPO proceeds 7. Rationale of such increase To meet the existing and future demand Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263